Levonadifloxacin is under clinical development by Wockhardt and currently in Phase II for Gram-Negative Bacterial Infections. According to GlobalData, Phase II drugs for Gram-Negative Bacterial Infections have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Levonadifloxacin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Levonadifloxacin overview

Levonadifloxacin (Emrok) is a broad spectrum synthetic benzoquinolizine fluoroquinolone antibacterial agent. It is formulated as powder for solution for intravenous route of administration. Emrok was indicated for the treatment of bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteraemia.

Levonadifloxacin (WCK-771) is under development for the treatment of bacterial infections caused by MRSA (Methicillin-Resistant Staphylococcus Aureus), VISA (vancomycin-intermediate Staphylococcus aureus), gram-negative bacteria, anaerobic bacteria, community-acquired bacterial pneumonia (HABP) . WCK-771 is administered intravenously. WCK 771 is a fluoroquinolone analog antibiotic. It targets DNA gyrase. The drug candidate is an arginine salt of levonadifloxacin and derived from the same chiral quinolone levonadifloxacin.

Wockhardt overview

Wockhardt is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. Its product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology, and diabetes. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS). It operates in India, the US, the UK, Ireland, Dubai, U.A.E. and has market presence in Brazil, France, Russia, Vietnam, Mexico, Philippines, Kenya, Nigeria, Ghana and others. Wockhardt is headquartered in Mumbai, Maharashtra, India.

For a complete picture of Levonadifloxacin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.